fluorouracil topical / Generic mfg. - LARVOL DELTA

BI16 The COAST (Contemporary Outcomes After cutaneous SCC in Transplant recipients) study: final results and implications for management following the first cutaneous squamous cell carcinoma in kidney transplant recipients. (PubMed, Br J Dermatol) - "Within 6 months of the first cSCC, 21% of KTRs were using topical chemoprevention (mainly 5-fluorouracil cream), 6% started systemic chemoprevention (acitretin or nicotinamide) and 5% used destructive therapies...Immunosuppression reduction strategies varied both within and between centres and were more frequently undertaken in patients with high-risk CSCC or in those on azathioprine (P = 0.01)...These data highlight the urgent need for prospective studies to identify optimal management of KTR following a first cSCC. Here we propose a risk stratification approach that may be used to guide prevention strategies."

Journal • Retrospective data • Dermatology • Non-melanoma Skin Cancer • Oncology • Solid Organ Transplantation • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P3 trial • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor

Characteristics, Management, and Outcomes of Rare Topical 5-Fluorouracil-Induced Cutaneous Eruptions: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal

Grenz Ray Therapy for Porokeratosis Ptychotropica: A Case Report. (PubMed, Case Rep Dermatol) - "She was previously unsuccessfully treated with topical, intralesional and oral corticosteroids, topical vitamin D analogues, topical simvastatin-cholesterol cream, topical fluorouracil cream, acitretin, and CO2 laser assisted photodynamic therapy. This is the first reported case of PP being treated with Grenz rays. With no effective treatment, Grenz therapy may present a potential effective treatment for some patients."

Journal

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Massachusetts General Hospital | Active, not recruiting ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Oncology • Solid Tumor

Overcoming seasonability of treatment in actinic keratosis: clinical practice with 4% 5-fluorouracil. (PubMed, Ital J Dermatol Venerol) - "Despite several limitations, this trial indicates that the treatment of actinic keratosis with 4% 5-fluorouracil together to the most suitable sunscreen can be performed with confidence even in the summer period."

Journal • Actinic Keratosis • Cognitive Disorders • Dermatology • Inflammation

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: OHSU Knight Cancer Institute | Trial completion date: Oct 2025 ➔ Jan 2027 | Trial primary completion date: Apr 2025 ➔ Dec 2024

Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy (ASH 2023) - "Samples were collected at various timepoints, including before fludarabine/cyclophosphamide lymphodepletion (pre-FC), D0, D7, D14, D28, and at the peak of IL-6 after CAR-T cell transfusion. Through proteomic analysis of cohort 1 and validation of cohort 2, we have preliminarily revealed that the core pathogenesis of CARAC involves the network regulation of immune, inflammatory, coagulation, and fibrinolytic systems."

Clinical • IO biomarker • Hematological Malignancies • Leukemia • Lymphoma • Oncology • IL6 • PROS1

Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL. (PubMed, Thromb Res) - "An effective CARAC risk prediction and stratification model was established. High-risk CARAC patients, particularly CARAC-DIC, were associated with significantly worse outcomes."

Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology

IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway (ASH 2024) - "These manifestations can be improved by IL-1β receptor inhibitor (Anakinra), Hsp90 inhibitor (17-DMAG hydrochloride), and kallikrein inhibitor (sebetralstat). Conclusion CARAC is characterized by bleeding and hypofibrinogenemia and is closely related to the inflammation-immune-endothelium-coagulation-fibrinolysis network. IL-1β of CRS promotes the release of Hsp90 by endothelial cells, which subsequently induces hyperfibrinolysis through the kallikrein-uPA pathway."

IO biomarker • Gastroenterology • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CDC37 • HSP90AA1 • HSP90AB1 • IL1B • IL6 • VCAM1

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov) - P1 | N=49 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2026 ➔ Jan 2028 | Trial primary completion date: Aug 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Appendix Cancer • Colorectal Cancer • Gastric Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • Uterine Cancer

NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2025 ➔ Jun 2026 | Trial primary completion date: Oct 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • POLE

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

Recurrent Lower Lip Swelling As An Unusual Presentation Of Actinic Cheilitis (ACAAI 2025) - "Case Description A 79-year-old woman was referred for recurrent lower lip swelling initially suspected as angioedema secondary to duloxetine use...Treatment options were discussed including liquid nitrogen cryotherapy, topical 5-fluorouracil (5-FU), and CO2 laser...Discussion This case underscores an atypical presentation of AC manifesting predominantly as recurrent lip swelling initially attributed to drug-induced angioedema. Considering AC’s potential for malignant transformation, clinicians must maintain a high index of suspicion for AC in patients presenting with recurrent lip swelling, particularly in those with chronic sun exposure or previous skin malignancy."

Bowens Disease • Cardiovascular • Dermatology • Immunology • Infectious Disease • Skin Cancer • Squamous Cell Carcinoma

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Emory University | Trial primary completion date: Sep 2025 ➔ Aug 2026

Trial primary completion date • Gastrointestinal Cancer • Oncology • Pain • Solid Tumor

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=120 | Active, not recruiting | Sponsor: Flemming Forsberg | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

HEMOSTATIC DERANGEMENTS DURING CAR-T CELL THERAPY (SIE 2025) - "Chimeric Antigen Receptor T-cell (CAR-T) therapy has reshaped the therapeutic landscape of B-cell malignancies, yet coagulopathy—collectively termed CAR-T-associated coagulopathy (CARAC)—is increasingly recognized as a clinically relevant toxicity...Prophylactic anticoagulation is reasonable in high-risk, non-thrombocytopenic patients, but evidence-based guidance is lacking.1,3Supportive strategies include maintaining fibrinogen >150-200 mg/dL, platelet transfusions, cryoprecipitate, and cautious use of antifibrinolytics.2,8Anti-cytokine therapies (corticosteroids, anakinra) may mitigate endothelial injury and indirectly improve coagulopathy.1,6Looking ahead, integration of biomarker panels and computational models may enable predictive, personalized risk assessment and targeted supportive interventions.9,10Embedding such tools in CAR-T care pathways could reduce morbidity and mortality from coagulopathy while preserving antitumor efficacy...Buechner J, Grupp SA,..."

CAR T-Cell Therapy • IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Venous Thromboembolism • IL10 • IL1B • TNFA

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2025 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2027

Trial completion date • Trial primary completion date • Cervical Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • Thoracic Cancer

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute

New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

TOPICAL 5-FLUOROURACIL IN THE TREATMENT OF VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN): EXPERIENCE FROM THE LARGEST TERTIARY CENTRE IN SINGAPORE AND LITERATURE REVIEW (IGCS 2025) - "There were 6 cases of VaIN 2 (54.5%) and 5 cases of VaIN 3 (45.5%), median follow-up 39 months (range 6-154). 1 patient was lost to follow-up after 6 months and still had persistent VaIN 2. 81.8% (n=9) had complete regression over median time of 6 months (range 1-27)."

Review • Oncology

Local skin reactions due to topical 5-fluorouracil treatment: Does DPYD-genotype matter? (ESMO 2025) - "While DPYD genotype may help guide treatment management in known variant carriers (e.g. imiquimod instead of 5-FU), current data do not support routine DPYD genotyping prior to topical 5-FU. Legal entity responsible for the study Erasmus University Medical Centre, Rotterdam, the Netherlands. Funding Stichting de Merel."

Oncology • DPYD

Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects. (PubMed, BMC Ophthalmol) - "Both 5-FU and surgical removal are effective and present a good security profile as primary therapies for OSSN. The two treatment modalities have no significant difference in the frequency of side effects or the time interval to recurrence."

Adverse events • Clinical • Journal • Retrospective data • Oncology • Ophthalmology • Pain • Squamous Cell Carcinoma

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: May 2026 ➔ Oct 2025

Enrollment open • Trial initiation date • Actinic Keratosis • Dermatology

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jan 2026 ➔ Jun 2025

Trial initiation date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

Topical 5-FU in Odontogenic Keratocyst: Clinical Outcomes and Molecular Insights. (PubMed, J Craniofac Surg) - "This study evaluated the efficacy of topical 5-fluorouracil (5-FU) as an adjunct to enucleation in 12 OKC patients. These findings support topical 5-FU as a safe, cost-effective, adjuvant therapy that potentially reducing recurrence risk. Validation in larger multicenter studies with extended follow-up is warranted."

Clinical data • Journal • CDK1 • TNFRSF10A • TNFRSF10D • TOP2A